Elevated liver enzymes often present a diagnostic challenge for clinicians due to their non-specific nature and the vast range of potential underlying etiologies. This article aims to provide a comprehensive approach to understand and manage this common clinical scenario.
It is crucial to understand that elevated liver enzymes are not a disease but a symptom of underlying hepatic or systemic pathology. They can be an indication of hepatocellular injury, cholestasis, or infiltrative diseases. A thorough history and clinical examination can often guide the clinician towards the underlying cause.
Liver function tests (LFTs) are a group of tests that give information about the state of a patient's liver. Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) are sensitive indicators of liver cell injury, while Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) indicate cholestasis. A pattern-based approach to LFTs can help narrow down the differential diagnoses.
Once the pattern of liver enzyme elevation is identified, the next step is to identify the etiology. This can be achieved through a combination of further investigations, including imaging studies, serological tests, and in some cases, a liver biopsy. The choice of investigation often depends on the clinical context and the suspected underlying cause.
Treatment of elevated liver enzymes involves addressing the underlying cause. This could range from lifestyle modifications in cases of non-alcoholic fatty liver disease, to antiviral therapy for viral hepatitis, or surgical intervention in cases of obstructive jaundice.
Decoding the cause of elevated liver enzymes requires a systematic approach, starting from a thorough clinical evaluation, followed by targeted investigations. Understanding the pattern of liver enzyme elevation and correlating it with the clinical context can significantly aid in reaching a diagnosis. Ultimately, the management of elevated liver enzymes is targeted towards treating the underlying cause.
1.
The need for more Latinx participants in Alzheimer's trials is urgent.
2.
Study reveals crucial gaps in oral cancer awareness in Middle East and North Africa
3.
Disparities in use of MRI to detect prostate cancer: Race and location may influence testing
4.
In breast-conserving surgery, is micro-CT a useful tool for determining tumor margins?
5.
Study offers clearer picture of childhood brain tumor survival
1.
Revolutionizing Cancer Care: The Promise of Early Detection and Biomarkers
2.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
3.
Comprehensive Standards in Oncology for Modern Medicine
4.
Cardio-Oncology: Managing Heart Failure in Survivors of Cancer
5.
Practical Standards in Hematology for Healthcare Excellence
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
4.
Nimotozumab Plus Chemo-radiotherapy v/s Placebo Plus Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation